Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 12/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL367122 | 0.85 | SCN9A (0.60) | SCN9ASCN5A | |
| SCHEMBL365758 | 0.83 | SCN9A (0.55) | SCN9ASCN5A | |
| SCHEMBL15018724 | 0.82 | SCN9A (0.71) | SCN9A | |
| SCHEMBL364907 | 0.82 | MRGPRX4 (0.53) | SCN9AMRGPRX4 | |
| Diethylamine SCHEMBL16239547 | 0.81 | SCN9A (0.57) | SCN9A | |
| SCHEMBL15018314 | 0.79 | SCN9A (0.70) | SCN9AS1PR1SCN5A | |
| SCHEMBL19411389 | 0.79 | SCN9A (0.56) | SCN9ASCN5A | |
| SCHEMBL15543365 | 0.77 | SCN9A (0.71) | SCN9ASCN5A | |
| SCHEMBL15543345 | 0.76 | SCN9A (0.53) | SCN9ASCN5A | |
| SCHEMBL16175270 | 0.74 | SCN9A (0.49) | SCN9AS1PR1SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2791108-B1 | SULFONAMIDE DERIVATIVES | PFIZER LTD (GB) | 2016-07-27 | — | — | EP | disclosed |
| EP-2791108-B1 | SULFONAMIDE DERIVATIVES | PFIZER LTD (GB) | 2016-07-27 | — | — | EP | disclosed |
| US-9102621-B2 | Acyl sulfonamide compounds | PFIZER LIMITED (GB) | 2015-08-11 | — | — | US | disclosed |
| US-9102621-B2 | Acyl sulfonamide compounds | PFIZER LIMITED (GB) | 2015-08-11 | — | — | US | disclosed |
| US-9102621-B2 | Acyl sulfonamide compounds | PFIZER LIMITED (GB) | 2015-08-11 | — | — | US | disclosed |
| US-9085517-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2015-07-21 | — | — | US | disclosed |
| US-9085517-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2015-07-21 | — | — | US | disclosed |
| US-9085517-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2015-07-21 | — | — | US | disclosed |
| EP-2593431-B1 | N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | PFIZER LTD (GB) | 2014-11-19 | — | — | EP | disclosed |
| EP-2593431-B1 | N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | PFIZER LTD (GB) | 2014-11-19 | — | — | EP | disclosed |
| US-20140315879-A1 | Sulfonamide Derivatives | PFIZER LIMITED (GB) | 2014-10-23 | — | — | US | disclosed |
| US-20140315879-A1 | Sulfonamide Derivatives | PFIZER LIMITED (GB) | 2014-10-23 | — | — | US | disclosed |
| EP-2791108-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited (GB) | 2014-10-22 | — | — | EP | disclosed |
| WO-2013088315-A1 | SULFONAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2013-06-20 | — | — | WO | disclosed |
| WO-2013088315-A1 | SULFONAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2013-06-20 | — | — | WO | disclosed |
| EP-2593431-A2 | CHEMICAL COMPOUNDS | Pfizer Limited (GB) | 2013-05-22 | — | — | EP | disclosed |
| US-20130109708-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| US-20130109708-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| US-20130109708-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| WO-2012007869-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109708-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | SCN9A 20/4885MRGPRX4 761/4885S1PR1 428/4885 |
| US-20140315879-A1 | Sulfonamide Derivatives | SCN7A, SCN1B, SCN1A | SCN9A 13/4885MRGPRX4 312/4885S1PR1 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.